Bio-tolerant substrata having analyte binding microarray

• US 20020192657A1
• Filed: 06/19/2001
• Published: 12/19/2002
• Est. Priority Date: 06/19/2001
• Status: Abandoned Application

• Current Assignee: Large Scale Biology Corporation, Large Scale Proteomics, Inc.
• Original Assignee: Large Scale Proteomics, Inc.
• Inventors: Anderson, N. Leigh, Erwin, Robert L.
• Application Number:
  US09/883,358
• Publication Number:
  US 20020192657A1
• Time in Patent Office: Days
• US Class Current: 435/6.11
• CPC Class Codes: G01N 33/54366 Apparatus specially adapted for solid-phase testing

Abstract

Contact lenses or similar ocular devices are disclosed that have specific binding molecule microarrays printed on or embedded in them to bind various analytes present in tears. Tear are used as a non-invasive alternative to the monitoring of proteins and other constituents found in serum, especially low molecular weight analytes and low abundance proteins. The devices can be placed in a developing reagent or the subject wearing the device can perceive changes in the visual filed that can be used to diagnose disease status as well as monitor various physiological and ambient environmental (exogenous) conditions.

Claims

1. An ocular device comprising a transparent substrate and a plurality of specific binding molecules bound thereto, each in a discrete location, wherein said specific binding molecules selectively bind analytes contained in ocular secretions upon contacting an ocular surface with said device.

2. The device of claim 1, wherein said specific binding molecules are selected from the group consisting of nucleic acids, proteins and receptors.

3. The device of claim 2, wherein said specific binding molecules are antibodies.

4. The device of claim 1, wherein said array comprises specific binding molecules deposited at addressable locations on said device.

5. The device of claim 4, wherein said addressable locations are obtained by spotting said specific binding molecules on the surface of said device.

6. The device of claim 1, wherein said device is a contact lens.

7. The device of claim 6, wherein said contact lens is an extended wear contact lens.

8. The device of claim 4, wherein said array comprises orientation markers.

9. A method of diagnosis using ocular secretions comprising:

a) contacting an ocular device comprising a transparent substrate and a plurality of specific binding molecules bound thereto, each in a discrete location, with the ocular surface of a subject, wherein said specific binding molecules selectively bind analytes contained in ocular secretions upon contacting an ocular surface with said device;

b) allowing the ocular device and ocular fluids to interact for a specified period of time; and

c) determining the presence, absence or amount of at least one analyte present in said secretion that selectively binds to the specific binding molecules,

wherein the presence, absence or amount of said at least one analyte correlates with a specific diagnosis.

10. The method of claim 9, further comprising removing said device after said specified period of time and before said determining the presence, absence or amount of at least one analyte.

11. The method of claim 9, wherein the determining step (d) is determined by immunoassay.

12. The method of claim 9, wherein the diagnosis is determined for disease markers associated with the diseases selected from the group consisting of silent heart attacks, silent strokes, tumors and diabetes.

13. The method of claim 9, wherein the diagnosis is accomplished by specific binding molecules selective for determining levels of analyte selected from the group consisting of hormones, cytokines, lymphokines, interleukins, interferons, chemokines and tumor, viral, bacterial, fungal and T-cell antigens and nucleic acids.

14. The method of claim 9, wherein the specific binding molecules are selected from the group consisting of, nucleic acids, proteins and receptors.

15. The method of claim 14, wherein the specific binding molecules are antibodies.

16. The method of claim 9 wherein said specific binding molecules are bound to an analyte-label conjugate.

17. The method of claim 16 wherein the label is a fluorescent, quenching, optically adsorbent, reflecting or other moiety that changes the optical properties of a portion of the ocular device.

18. The method of claim 16 wherein said label is an enzyme that is inactive when bound, and upon interaction with competitive analyte in the ocular secretion, the analyte is freed thereby activating the enzyme.

19. The method of claim 18, wherein the activated enzyme metabolizes a substrate producing a color change in, on or about the device that is perceptible to said subject.

20. A method of detecting a harmful agent using a device placed on an ocular surface comprising:

(a) contacting an ocular device comprising a transparent substrate and a plurality of specific binding molecules bound thereto, each in a discrete location, with the ocular surface of a subject, wherein said specific binding molecules selectively bind analytes from the surrounding ambient environment,

(b) allowing the ocular device and ambient environment to interact for a specified period of time; and

(c) determining the presence, absence or amount of a harmful agent in said environment that selectively binds to the specific binding molecules,

wherein the presence of toxic agent binding correlates with a presence of a toxic agent in the ambient environment.

21. The method of claim 20, wherein said harmful agent is selected from the group consisting of tear gas, mustard gas, nerve gas, toxins and biologics.

22. The method of claim 20, wherein said harmful agent is generated from a high air pollution source.

23. The method of claim 22, wherein said high air pollution source is selected from the group consisting of a factory, toxic waste site, fuel station and combustion sources.

25. The method of claim 24, wherein said vaccine is a tumor antigen.

26. The method of claim 25, wherein the tumor antigen is a non-Hodgkin'"'"'s Lymphoma vaccine or an epitope thereof.

27. The method of claim 24, further comprising removing said ocular device after said specified period of time and before said determining the presence of an immunoglobulin.

24. A method of determining the response to a vaccine comprising:

a) contacting an ocular device comprising at least one vaccine component with an ocular surface of an immunized subject;

b) allowing the ocular device and ocular fluid to interact for a specified period of time; and

c) determining the presence of an immunoglobulin contained in said secretion that selectively binds to the vaccine component attached to the ocular device,

wherein the presence of said immunoglobulin correlates with a specific response to said vaccine.

28. A method of determining a toxic or effective response to a chemical comprising:

a) contacting an ocular device comprising an array having a plurality of specific binding molecules with an ocular surface of a dosed subject;

b) allowing the ocular device and ocular surface to interact for a specified period of time;

c) determining the presence of an analyte comprised in said secretion that is produced in a toxic or effective response and which selectively binds to the device,

wherein the presence of said toxic substance correlates with a negative response to said drug.

29. A method of determining the response to an allergen comprising:

a) contacting an ocular device comprising an array of allergens with an ocular surface of a subject;

b) allowing the ocular device and ocular fluid to interact for a specified period of time;

c) removing said device after specified time period;

d) determining the presence, absence or amount of IgE comprised in said secretion that selectively binds to the allergens in or on the ocular device,

wherein the presence of IgE correlates with a specific response to said allergen.

30. A method of detecting an analyte in ocular secretions comprising:

contacting an ocular device comprising a transparent substrate and having an analyte adsorbing region for reversibly adsorbing the analyte

allowing the ocular device and ocular fluids to interact for a period of time sufficient for analyte to adsorb to said ocular device

removing the ocular device

removing adsorbed analyte from the ocular device; and

determining the presence, absence or amount of at least one analyte present in said secretion that bound to the ocular device

wherein the presence, absence or amount of said at least one analyte correlates with a specific diagnosis.

31. The method of claim 30, wherein the determining step (d) is determined by immunoassay.

32. The method of claim 30, wherein the diagnosis is determined for disease markers associated with the diseases selected from the group consisting of silent heart attacks, silent strokes, tumors and diabetes.

33. A therapeutic implantable device which is capable of detecting an analyte in body fluids comprising a therapeutic implantable device having a region which is a substrate having a plurality of specific binding molecules bound thereto, each in a discrete location, wherein said specific binding molecules selectively bind analytes contained in body fluids upon contact with said device, and wherein said region does not interfere with the therapeutic function of the device.

34. The device of claim 33, wherein said specific binding molecules are selected from the group consisting of nucleic acids, proteins and receptors.

35. The device of claim 34, wherein said specific binding molecules are antibodies.

36. The device of claim 33, wherein said specific binding molecules are deposited at addressable locations on said device.

37. The device of claim 36, wherein said addressable locations are obtained by spotting said specific binding molecules on the surface of said device.

39. The device of claim 38, wherein said specific binding molecules are selected from the group consisting of nucleic acids, proteins and receptors.

40. The device of claim 39, wherein said specific binding molecules are antibodies.

41. The device of claim 38, wherein said specific binding molecules are deposited at addressable locations on said device.

42. The device of claim 41, wherein said addressable locations are obtained by spotting said specific binding molecules on the surface of said device.

38. A vessel or conduit for holding body fluids which is capable of detecting an analyte in body fluids having a region contacting said body fluids which is a substrate having a plurality of specific binding molecules bound thereto, each in a discrete location, wherein said specific binding molecules selectively bind analytes contained in said body fluids upon contact with said vessel or conduit.